Junsik Park

Puch'on, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Histology-specific ADC target landscapes in ovarian cancer and therapy-associated antigen downshift after ADC exposure.

Histology-specific ADC target landscapes in ovarian cancer and therapy-associated antigen downshift after ADC exposure.

Journal: Gynecologic oncology

Published: April 14, 2026

Formation of an endometrial epithelial monolayer in a microfluidic device with human tissue-derived endometrial organoids.

Formation of an endometrial epithelial monolayer in a microfluidic device with human tissue-derived endometrial organoids.

Journal: Lab on a chip

Published: January 06, 2026

Prognostic implications of HER2 in ovarian cancer: Associations with homologous recombination deficiency and folate receptor alpha expression.

Prognostic implications of HER2 in ovarian cancer: Associations with homologous recombination deficiency and folate receptor alpha expression.

Journal: Gynecologic oncology

Published: August 26, 2025

Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial.

Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial.

Journal: The Lancet. Oncology

Published: August 21, 2025

Novel anti-CD73-IL-2v bispecific fusion protein augments antitumor immunity by alleviating immunosuppressive adenosine pathways in CD8+ T cells.

Novel anti-CD73-IL-2v bispecific fusion protein augments antitumor immunity by alleviating immunosuppressive adenosine pathways in CD8+ T cells.

Journal: Journal for immunotherapy of cancer

Published: February 26, 2025

Efficacy of Chemotherapy Following Prior PARP-Inhibitor Treatment in Patients with Ovarian Cancer.

Efficacy of Chemotherapy Following Prior PARP-Inhibitor Treatment in Patients with Ovarian Cancer.

Journal: Cancer research and treatment

Published: December 23, 2024

Neoadjuvant Chemotherapy with Dual Immune Checkpoint Inhibitors for Advanced-Stage Ovarian Cancer: Final Analysis of TRU-D Phase II Nonrandomized Clinical Trial.

Neoadjuvant Chemotherapy with Dual Immune Checkpoint Inhibitors for Advanced-Stage Ovarian Cancer: Final Analysis of TRU-D Phase II Nonrandomized Clinical Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 09, 2024

Co-blockade of TGFβ and PD-1 Reinvigorates Glioblastoma-Infiltrating CD8+ T Cells That Characteristically Upregulate TGFβRI Expression.

Co-blockade of TGFβ and PD-1 Reinvigorates Glioblastoma-Infiltrating CD8+ T Cells That Characteristically Upregulate TGFβRI Expression.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 11, 2024

OPERA: a phase II trial of oregovomab plus non-platinum chemotherapy in PARP inhibitor/platinum-resistant ovarian cancer.

OPERA: a phase II trial of oregovomab plus non-platinum chemotherapy in PARP inhibitor/platinum-resistant ovarian cancer.

Journal: Future oncology (London, England)

Published: June 28, 2024

Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8+ TILs based on BRCA1/2 mutation status in epithelial ovarian cancers.

Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8+ TILs based on BRCA1/2 mutation status in epithelial ovarian cancers.

Journal: Journal for immunotherapy of cancer

Published: June 21, 2024

Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D.

Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D.

Journal: Journal for immunotherapy of cancer

Published: September 22, 2023

Anti-4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade.

Anti-4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 21, 2023

Showing 1-12 of 41

Last Updated: 09/26/2026